Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette

Journal of Virology

Volumn 72, Issue 3, 1998, Pages 2289-2296

  Massie, Bernard ^a   Couture, France ^a   Lamoureux, Linda ^a   Mosser, Dick D ^a   Guilbault, Claire ^b   Jolicoeur, Pierre ^a   Bélanger, François ^a   Langelier, Yves ^b  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b Institut du Cancer de Montreal   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIN; RECOMBINANT PROTEIN; TETRACYCLINE;

ADENOVIRUS; ARTICLE; CYTOMEGALOVIRUS; CYTOTOXICITY; EXPRESSION VECTOR; GENE CASSETTE; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS RECOMBINANT;

EID: 0031888264     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.3.2289-2296.1998     Document Type: Article

References (41)

1. Acsadi, G., A. Jani, B. Massie, M. Simoneau, P. Holland, K. Blaschuk, and G. Karpati. 1994. A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity. Hum. Mol. Genet. 3:579-584.
2. Acsadi, G., B, Massie, and A, Jani. 1995. Adenovirus-mediated gene transfer into striated muscles. J. Mol. Med. 73:165-180.
3. Anton, M., and F. L. Graham. 1995. Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression. J. Virol. 69:4600-4606.
4. Berkner, K. L. 1988. Development of adenovirus vector for the expression of heterologous genes. BioTechniques 6:616-629.
5. Berkner, K. L. 1992. Expression of heterologous sequences in adenoviral vectors. Curr. Top. Microbiol. Immunol. 158:39-66.
6. Bramson, J., M. Hitt, W. S. Gallicban, K. L. Rosenthal, J. Gauldie, and F. L. Graham. 1996. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and vivo production of biologically active interleukin-12. Hum. Gene Ther. 7:333-342.
7. Connelly, S., J. M. Gardner, A. McClelland, and M. Kaleko. 1996. High-level tissue-specific expression of functional human factor VIII in mice. Hum. Gene Ther. 7:183-195.
8. Fiering, N. S., M. Roederer, G. P. Nolan, D. R. Micklem, D. R. Parks, and L. A. Herzenberg. 1991. Improved FACS-Gal: flow cytrometric analysis and sorting of viable eukaryotic cells expressing reporter gene constructs. Cytometry 12:291-301.
9. Garnier, A., J. Côté, I. Nadeau, A. Kamen, and B. Massie. 1994. Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells. Cytotechnology 15:145-155.
10. Gluzman, Y., H. Reichl, and D. Solnick. 1982. Helper-free adenovirus type 5 vectors, p. 187-192. In Y. Gluzman (ed.), Eucaryotic viral vectors. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
11. Gossen, M., A. L. Bonin, S. Freundlieb, and H. Bujard. 1994. Inducible gene expression systems for higher eukaryotic cells. Curr. Opin. Biotechnol. 5: 516-520.
12. Gossen, M., and H. Bujard. 1992. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89:5547-5551.
13. Gossen, M., S. Freundlieb, G. Bender, G. Müller, W. Hillen, and H. Bujard. 1995. Transcriptional activation by tetracyclines in mammalian cells. Science 268:1766-1769.
14. Graham, F. L., and L. Prevec. 1992. Adenovirus-based expression vectors and recombinant vaccines, p. 363-390. In R. W. Ellis (ed.), Vaccines: new approaches to immunological problems. Butterworth-Heinemann, Boston, Mass.
15. Graham, F. L., and L. Prevec. 1995. Methods for construction of adenovirus vectors. Mol. Biotechnol. 3:207-220.
16. Graham, F. L., J. R. Smiley, W. C. Russell, and R. Nairn. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-72.
17. Howe, J. R., B. V. Skryabin, S. M. Belcher, C. A. Zerillo, and C. Schmauss. 1995. The responsiveness of a tetracycline sensitive expression system differs in different cell lines. J. Biol. Chem. 270:14168-14174.
18. Jani, A., H. Lochmüller, G. Acsadi, M. Simoneau, J. Huard, A. Garnier, G. Karpati, and B. Massie. 1997. Generation, validation and large scale production of adenoviral recombinants with large inserts such as 6.3 kb human dystrophin cDNA. J. Virol. Methods 64:111-124.
19. Lamarche, N., B. Massie, M. Richer, H. Paradis, and Y. Langelier. 1990. High level expression in 293 cells of the herpes simplex virus type 2 ribonucleotide reductase subunit 2 using an adenovirus vector. J. Gen. Virol. 71:1785-1792.
20. Langelier, Y., J. Lippens, S. Bergeron, C. Guilbault, F. Couture, and B. Massie. Unpublished data.
21. Lochmüller, H., A. Jani, J. Huard, S. Prescott, M. Simoneau, B. Massie, G. Karpati, and G. Acsadi. 1994. Emergence of early region 1 (E1)-containing replication competent adenovirus in stocks of replication defective adenovirus recombinants (ΔE1 + ΔE3) during multiple passages in 293 cells. Hum. Gene Ther. 5:1485-1491.
22. Lutz, P., and C. Kédinger. 1996. Properties of the adenovirus IVa2 gene product, an effector of late-phase-dependent activation of the major late promoter. J. Virol. 70:1396-1405.
23. Manthorpe, M., F. Cornefert-Jensen, J. Hartikka, J. Feigner, A. Rundell, M. Margalth, and V. J. Dwarki. 1993. Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Hum. Gene Ther. 4:419-421.
24. Massie, B., J. Dionne, N. Lamarche, J. Fleurent, and Y. Langelier. 1995. Improved adenovirus vector provides herpes simplex virus ribonucleotide reductase R1 and R2 subunits very efficiently. Bio/Technology 13:602-608.
25. Mosser, D. D., A. W. Caron, L. Bourget, P. Jolicoeur, and B. Massie. 1997. Use of a dicistronic expression cassette encoding the green-fluorescent protein for the screening and selection of cells expressing inducible gene products. BioTechniques 22:150-161.
26. Paquet, L., B. Massie, and R. E. Mains. 1996. Proneuropeptide Y is proteolytically processed by the prohormone convertase PC2 in sympathetic neurons using adenoviruses. J. Neurosci. 16:964-973.
27. Paradis, H., P. Gaudreau, B. Massie, N. Lamarche, C. Guilbault, S. Gravel, and Y. Langelier. 1991. Affinity purification of active subunit 1 herpes simplex virus type 1 ribonucleotide reductase exhibiting a protein kinase activity. J. Biol. Chem. 266:9647-9651.
28. 1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol. Cell. Biol. 14:1669-1679.
29. Schockett, P., M. Difilippantonio, N. Hellman, and D. G. Schatz. 1995. A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. Proc. Natl. Acad. Sci. USA 92:6522-6526.
30. Schultze, N., Y. Burki, Y. Lang, U. Certa, and H. Bluethmann. 1996. Efficient control of gene expression by single step integration of the tetracycline system in transgenic mice. Nat. Biotechnol. 14:499-503.
31. Sheay, W., S. Nelson, I. Martinez, T.-H. T. Chu, S. Bhatia, and R. Dornburg. 1993. Downstream insertion of the adenovirus tripartite leader sequence enhances expression in universal eukaryotic vectors. BioTechniques 15:857-862.
32. Stratford-Perricaudet, L. D., and M. Perricaudet. 1994. Gene therapy: the advent of adenovirus, p. 344-362. In Jon A. Wolff (ed.), Gene therapeutics: methods and applications of direct gene transfer. Birkhauser Boston, Cambridge, Mass.
33. Suarez, P., M. Diaz-Guerra, C. Prieto, M. Esteban, J. M. Castro, A. Nieto, and J. Ortin. 1996. Open reading frame 5 of porcine reproductive and respiratory syndrome virus as a cause of virus-induced apoptosis. J. Virol. 70:2876-2882.
34. Teodoro, J. G., and P. E. Branton. 1997. Regulation of apoptosis by viral gene products. J. Virol. 71:1739-1746.
35. Trapnell, B. C., and M. Gorzilia. 1994. Gene therapy using adenoviral vectors. Curr. Opin. Biotechnol. 5:617-625.
36. White, E., P. Sabbatini, M. Debbas, W. S. Wold, D. I. Kusher, and L. R. Gooding. 1992. The 19-kilodalton adenovirus E1B transforming protein inhibits programmed cell death and prevents cytolysis by tumor necrosis factor alpha. Mol. Cell. Biol. 12:2570-2580.
37. Wilkinson, G. W. G., and A. Akrigg. 1991. The cytomegalovirus major immediate early promoter and its use in eukaryotic expression systems. Adv. Gene Technol. 2:287-310.
38. Wilkinson, G. W. G., and A. Akrigg. 1992. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res. 9:2233-2239.
39. Wills, K. N., D. C. Manaval, P. Menzel, P. H. Matthew, S. Syjiputo, M.-T. Vaillancourt, W.-M. Huang, D. E. Johnson, S. C. Anderson, S. F. Wen, R. Bookstein, M. H. Shepard, and R. J. Gregory. 1994. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum. Gene Ther. 5:1079-1088.
40. Wu, L., D. S. Rosser, M. C. Schmidt, and A. Berk. 1987. A TATA box implicated in E1a transcriptional activation of a simple adenovirus promoter. Nature 326:512-515.
41. Xu, Z. Z., V. Krougliak, L. Prevec, F. L. Graham, and G. W. Both. 1995. Investigation of promoter function and animal cells infected with human recombinant adenoviruses expressing rotavirus antigen VP7sc. J. Gen. Virol. 76:1971-1980.